Hepatitis B
HIVandHepatitis.com 2017 Conference Coverage
- Details
- Category: HIV Treatment
- Published on Saturday, 30 December 2017 00:00
- Written by HIVandHepatitis.com
Article listings by topic for HIVandHepatitis.com conference coverage in 2017, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, IAS Conference on HIV Science, and AASLD Liver Meeting.
AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 December 2017 00:00
- Written by Liz Highleyman
JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 15 December 2017 00:00
- Written by Liz Highleyman
ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the infection, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
A majority of chronic hepatitis B patients treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve "functional control" of hepatitis B virus (HBV), according to a late-breaking poster presentation at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.
U.S. Approves New Hepatitis B Vaccine as Public Health Agencies Update Guidelines
- Details
- Category: HBV Vaccines
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
On November 9 the U.S. Food and Drug Administration(FDA) approved Heplisav-B, a new vaccine that provides protection against all known subtypes of hepatitis B virus (HBV) with 2 rather than 3 doses, which is expected to reduce the number of people who do not complete the vaccine series.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases, AASLD), October 20-24, 2017, in Washington, DC.
More Articles...
- Coverage of the 2017 AASLD Liver Meeting
- AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- FDA Approves Nivolumab Immunotherapy for Liver Cancer
- FDA Approves Nivolumab Immunotherapy for Liver Cancer
- PAS 2017: Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection
Web Design and Development by